Intravenous (IV) Hydrocortisone for TKA (Total Knee Arthroplasty)
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
In this study, total knee replacement patients will be determined to be stiff or non-stiff
preoperatively. Stiffness designation is determined by preoperative range of motion (if
flexion is < 100 degrees, or extension lag is > 10 degrees). The stiff and non-stiff groups
will both be randomized to two groups to receive either intravenous hydrocortisone or a
placebo at 3 intervals postoperatively. Patients will be followed up with in hospital and via
the phone on postoperative day (POD) 1 and 2, as well as 6 weeks, 6 months, 1 year, and 2
years postoperatively. Patients will also have blood drawn preoperatively in the OR, on POD1,
at their 6 week followup, and at their 1 and 2 year follow ups. This blood will be processed
and analyzed.